专题：Chronic Myeloid Leukemia Treatments

This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.
最新文献
Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan

article Full Text OpenAlex

Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems

article Full Text OpenAlex

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

article Full Text OpenAlex

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

article Full Text OpenAlex

Therapy‐Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review

article Full Text OpenAlex

Zanubrutinib‐Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia

article Full Text OpenAlex

Incidence and Management of Tirabrutinib-associated Cutaneous Adverse Events: A Case Series

article Full Text OpenAlex

Tolebrutinib and the FDA

article Full Text OpenAlex

[Translated article] Acute esophageal necrosis in a patient with lung cancer under treatment with osimertinib: Case report

article Full Text OpenAlex

Ultra-Sensitive Mutation Detection Technology in Myeloid Neoplasms: New Tools for Patient Monitoring

article Full Text OpenAlex

近5年高被引文献
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

article Full Text OpenAlex 431 FWCI126.8925

Two Phase 3 Trials of Baricitinib for Alopecia Areata

article Full Text OpenAlex 415 FWCI87.9069

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

review Full Text OpenAlex 381 FWCI84.9338

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

article Full Text OpenAlex 329 FWCI97.0227

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

article Full Text OpenAlex 269 FWCI36.5665

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

article Full Text OpenAlex 260 FWCI36.7269

Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

article Full Text OpenAlex 223 FWCI32.2759

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

article Full Text OpenAlex 220 FWCI42.2977

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

article Full Text OpenAlex 219 FWCI31.0612

Overview of Methotrexate Toxicity: A Comprehensive Literature Review

review Full Text OpenAlex 209 FWCI39.7044